evokepharma.com (EVOK): רווח נקי למניה ב-12 החודשים האחרונים

Evoke Pharma, Inc. (EVOK) relies on a stable staff of biochemists and gastroenterology experts. The change in the rolling annual EPS on GURU.Markets demonstrates profit dynamics, where the value has stabilized at -2.39. Business revenues are based on the sale of the Gimoti nasal spray. The product is in demand among gastroenterologists and patients with diabetic gastroparesis seeking an effective alternative to traditional tablets.
פילוחים אנליטיים ודוחות נתונים של חברת Evoke Pharma Inc (EVOK)

This metric is calculated as the ratio of annual net income to the weighted average number of common shares. The metric determines the actual beneficiary income, eliminating distortions from share issuances or share buybacks. For Evoke Pharma, Inc. (EVOK), reliance on contract manufacturing organizations (CMOs) directly impacts margins and the bottom line. By analyzing the TTM fundamental earnings per share trend on the GURU.Markets platform, an investor can identify hidden debt risks behind apparent stability.